RECCE PHARMACEUTICALS LTD — Director's Dealing 2019

Dec 19, 2019

Appendix 3Y Change of Director’s Interest Notice

Rule 3.19A.2

Appendix 3Y

Change of Director’s Interest Notice

Information or documents not available now must be given to ASX as soon as available. Information and documents given to ASX become ASX’s property and may be made public.

Introduced 30/09/01 Amended 01/01/11

Name of entity Recce Pharmaceuticals Ltd (Company) ABN 73 124 849 065

We (the entity) give ASX the following information under listing rule 3.19A.2 and as agent for the director for the purposes of section 205G of the Corporations Act.

the director for the purposes of section	205G of the Corporations Act.
Name of Director	Dr Justin Ward
Date of last notice	12 July 2019

Part 1 - Change of director’s relevant interests in securities

In the case of a trust, this includes interests in the trust made available by the responsible entity of the trust

Note: In the case of a company, interests which come within paragraph (i) of the definition of “notifiable interest of a director” should be disclosed in this part.

Direct or indirect interest	Direct
Nature of indirect interest	N/A
(including registered holder)
Note: Provide details of the circumstances giving rise
to the relevant interest.
Date of change	19 December 2019
No. of securities held prior to	115,488 fully paid ordinary shares
change
Class	Fully paid ordinary shares
Number acquired	43,478 fully paid ordinary shares
Number disposed	N/A
Value/Consideration	Nil cash consideration.
Note: If consideration is non-cash, provide details andestimated valuation	43,478 fully paid ordinary shares were issued to DrWard as part of his remuneration for his services to
	the Company.
No. of securities held after change	158,966 fully paid ordinary shares

• See chapter 19 for defined terms.

01/01/2011

Appendix 3Y Page 1

Appendix 3Y Change of Director’s Interest Notice

Nature of change 43,478 fully paid ordinary shares were issued to Dr Example: on-market trade, off-market trade, exercise Ward as part of his remuneration for his services to of options, issue of securities under dividend the Company. reinvestment plan, participation in buy-back The Company obtained shareholder approval to issue the fully paid ordinary shares to Dr Ward at the Annual General Meeting held on 25 November 2019.

Part 2 – Change of director’s interests in contracts

Note: In the case of a company, interests which come within paragraph (ii) of the definition of “notifiable interest of a director” should be disclosed in this part.

Detail of contract	N/A
Nature of interest	N/A
Name of registered holder	N/A
(if issued securities)
Date of change	N/A
No. and class of securities to which interest related prior to	N/A
change
Note: Details are only required for a contract in relation to which the interest has changed
Interest acquired	N/A
Interest disposed	N/A
Value/Consideration	N/A
Note: If consideration is non-cash, provide details and an estimated valuation
Interest after change	N/A

Part 3 – +Closed period

Part 3 – +Closed period
Were the interests in the securities or contracts detailed abovetraded during a+closed period where prior written clearance wasrequired?	No
If so, was prior written clearance provided to allow the trade toproceed during this period?	N/A
If prior written clearance was provided, on what date was thisprovided?	N/A

• See chapter 19 for defined terms.

Appendix 3Y Page 2

01/01/2011